Future clinical trials will be conducted to investigate whether the combination of chloroquine and venetoclax can prevent disease recurrence.
Although new drugs have been developed to induce cancer cell death in individuals with acute myeloid leukemia, the leukemic cells often develop resistance and evade the drugs’ effects within a year.
Recently, research conducted using both human tissue samples and mouse models has uncovered that the resistance of leukemia cells to the widely used drug venetoclax is due to an abrupt surge in the breakdown and turnover of mitochondria. These structures within the cell play a crucial role in generating energy and also signal the cell to undergo programmed cell death under certain adverse conditions.
Led by scientists at NYU Langone Health and its Perlmutter Cancer Center, the study showed that mitophagy helps leukemia cells to evade the killing effects of venetoclax, a drug in a class of medications known as BH3 mimetics.
In a study recently published in the journal Cancer Discovery, researchers found that the levels of several genes associated with mitophagy were increased in 20 leukemia patient samples compared with normal controls. The level of these genes was even higher in samples from leukemia patients with drug resistance than in those leukemic patients who were not. Particularly notable was the increased expression of the gene for Mitofusin-2 (MFN2), which codes for a key protein in the outer mitochondrial membrane.
Further experiments using mice into which bone marrow from acute myeloid leukemia patients was transplanted showed that the drug chloroquine, a known mitophagy inhibitor, restored the ability of venetoclax to kill the cancer cells.
“Overcoming resistance to BH3 mimetic drugs like venetoclax is of unique clinical significance because these medications are often used for treating people with acute myeloid leukemia,” said study co-lead investigator Christina Glytsou, Ph.D., a former postdoctoral researcher at NYU Grossman School of Medicine and now an assistant professor at Rutgers University.
“Acute myeloid leukemia is notoriously difficult to treat, with fewer than a third of those affected living longer than five years after their diagnosis, so it is important to maximize the impact of existing therapies,” said study co-lead investigator Xufeng Chen, Ph.D., an instructor in the Department of Pathology at NYU Grossman.
“Our preclinical findings suggest that combining BH3 mimetics like venetoclax with either MFN2 or general mitophagy inhibitors could possibly serve as a future therapy for acute myeloid leukemia, as current drug treatments are stalled due to drug resistance,” said study senior investigator Iannis Aifantis, Ph.D.
Aifantis, the Hermann M. Biggs Professor and chair of the Department of Pathology at NYU Grossman and Perlmutter, says the research team plans to design a clinical trial to test whether chloroquine, when used in combination with venetoclax, prevents drug resistance in people with acute myeloid leukemia.
Speaking about other study results, the researchers say they not only found that MFN2 was overly active in people with drug-resistant disease, but also that cancer cells exposed to similar cell-death-inducing compounds demonstrated a doubling in mitophagy rates.
Additional testing in cancer cells engineered to lack MFN2 showed increased sensitivity to drugs similar to venetoclax compared with cells that had functional MFN2. The new study and previous research by the team showing misshapen mitochondria in drug-resistant leukemic cells confirmed that increased mitophagy was the source of the problem.
Acute myeloid leukemia, the most common form of adult leukemia, originates in the bone marrow cells and involves the rapid buildup of abnormal blood cells. The blood cancer results in the deaths of more than 11,500 Americans annually. Current treatments include chemotherapy and a limited number of targeted drug therapies. Bone marrow transplantation has also been used when other options fail.
Reference: “Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia” by Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, Wafa Al-Santli, Hua Zhou, Bettina Nadorp, Soobeom Lee, Audrey Lasry, Zhengxi Sun, Dimitrios Papaioannou, Michael Cammer, Kun Wang, Tomasz Zal, Malgorzata Anna. Zal, Bing Z. Carter, Jo Ishizawa, Raoul Tibes, Aristotelis Tsirigos, Michael Andreeff, Evripidis Gavathiotis and Iannis Aifantis, 24 April 2023, Cancer Discovery.
DOI: 10.1158/2159-8290.CD-22-0601
The study was funded by the National Science Foundation. Additional funding support was provided by the Leukemia & Lymphoma Society and by AstraZeneca, which provided several of the BH3 mimetic drugs used in these experiments.
Aifantis has received additional research funding from AstraZeneca. This arrangement is being managed in accordance with the policies and practices of NYU Langone Health.
News
Pupil size in sleep reveals how memories are processed
Cornell University researchers have found that the pupil is key to understanding how, and when, the brain forms strong, long-lasting memories. By studying mice equipped with brain electrodes and tiny eye-tracking cameras, the researchers [...]
Stanford’s Vaccine Breakthrough Boosts Flu Protection Like Never Before
Stanford Medicine researchers have developed a new method for influenza vaccination that encourages a robust immune response to all four common flu subtypes, potentially increasing the vaccine’s efficacy. In laboratory tests using human tonsil [...]
Water’s Worst Nightmare: The Rise of Superhydrophobic Materials
New materials with near-perfect water repellency offer potential for self-cleaning surfaces in cars and buildings. Scientists from Karlsruhe Institute of Technology (KIT) and the Indian Institute of Technology Guwahati (IITG) have developed a surface [...]
Japanese dentists test drug to help people with missing teeth regrow new ones
Japanese dentists are testing a groundbreaking drug that could enable people with missing teeth to grow new ones, reducing the need for dentures and implants, AFP recently reported. Katsu Takahashi, head of oral surgery at [...]
An AI system has reached human level on a test for ‘general intelligence’
A new artificial intelligence (AI) model has just achieved human-level results on a test designed to measure "general intelligence." On December 20, OpenAI's o3 system scored 85% on the ARC-AGI benchmark, well above the previous AI best [...]
According to Researchers, Your Breathing Patterns Could Hold the Key to Better Memory
Breathing synchronizes brain waves that support memory consolidation. A new study from Northwestern Medicine reports that, much like a conductor harmonizes various instruments in an orchestra to create a symphony, breathing synchronizes hippocampal brain waves to [...]
The Hidden Culprit Behind Alzheimer’s Revealed: Microglia Under the Microscope
Researchers at the CUNY Graduate Center have made a groundbreaking discovery in Alzheimer’s disease research, identifying a critical link between cellular stress in the brain and disease progression. Their study focuses on microglia, the brain’s immune [...]
“Mirror Bacteria” Warning: A New Kind of Life Could Pose a Global Threat
Mirror life, a concept involving synthetic organisms with reversed molecular structures, carries significant risks despite its potential for medical advancements. Experts warn that mirror bacteria could escape natural biological controls, potentially evolving to exploit [...]
Lingering Viral Fragments: The Hidden Cause of Long COVID
Long COVID, affecting 5-10% of COVID-19 patients, might be caused by the enduring presence of the virus in the body. Research suggests that viral fragments, possibly live, linger and lead to symptoms. Addressing this involves antiviral treatments, enhanced [...]
Hidden Scars: How COVID Lockdowns Altered Teen Brains Forever
Research from the University of Washington revealed that COVID-19 lockdowns led to accelerated cortical thinning in adolescents, impacting brain development significantly. This effect was more pronounced in females than males, raising concerns about long-term brain health. The study [...]
Simple Blood Test To Detect Dementia Before Symptoms Appear
UCLA researchers have identified placental growth factor (PlGF) as a potential blood biomarker for early detection of cognitive impairment and dementia. High PlGF levels correlate with increased vascular permeability, suggesting its role in the development [...]
Investing Goldman Sachs asks ‘Is curing patients a sustainable business model?’
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering “gene therapy” treatment: cures could be bad for business in the long run. “Is curing patients [...]
The risks of reversed chirality: Study highlights dangers of mirror organisms
A groundbreaking study evaluates the feasibility, risks, and ethical considerations of creating mirror bacteria with reversed chirality, highlighting potential threats to health and ecosystems. In a recent study published in Science, a team of researchers [...]
Alarming Mutation in H5N1 Virus Raises Pandemic Red Flags
NIH-funded study concludes that the risk of human infection remains low A recent study published in Science and funded by the National Institutes of Health (NIH) has found that a single alteration in a protein on the surface [...]
Scientists Discover Genetic Changes Linked to Autism, Schizophrenia
The Tbx1 gene influences brain volume and social behavior in autism and schizophrenia, with its deficiency linked to amygdala shrinkage and impaired social incentive evaluation. A study published in Molecular Psychiatry has linked changes in brain [...]
How much permafrost will melt this century, and where will its carbon go?
Among the many things global warming will be melting this century—sea ice, land glaciers and tourist businesses in seaside towns across the world—is permafrost. Lying underneath 15% of the northern hemisphere, permafrost consists of [...]
